These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36047134)

  • 41. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma.
    Kubo T; Sugawara T; Shinkawa T; Kurisu T; Kouzen N; Tanaka T; Fukuta F; Yamasaki K; Sugita S; Matsuo K; Morita R; Hirohashi Y; Tsukahara T; Kanaseki T; Hasegawa T; Masumori N; Torigoe T
    Immunol Med; 2021 Jun; 44(2):136-141. PubMed ID: 32634346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma.
    Patel V; Elias R; Formella J; Schwartzman W; Christie A; Cai Q; Malladi V; Kapur P; Vazquez M; McKay R; Pedrosa I; Hannan R; Hammers H; Brugarolas J
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33139246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.
    Bando Y; Furukawa J; Okamura Y; Hara T; Terakawa T; Nakano Y; Fujisawa M
    Anticancer Res; 2022 Feb; 42(2):973-979. PubMed ID: 35093897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Acute meningoencephalitis caused by Streptococcus pneumoniae, mimicking acute disseminated encephalomyelitis].
    Kureshiro J; Kuzumoto Y; Aomatsu H; Kusunoki S
    Rinsho Shinkeigaku; 2008 Apr; 48(4):255-8. PubMed ID: 18453157
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characteristic cerebrospinal fluid findings in immune checkpoint inhibitor-related peripheral neuropathy: A case report.
    Wako S; Ikeguchi R; Toda K; Kobayashi M; Miyata R; Kuramochi H; Ichihara A; Shimizu Y; Kitagawa K
    J Neuroimmunol; 2023 Jan; 374():578010. PubMed ID: 36508929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
    Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
    Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
    Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
    Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
    Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
    Gao CA; Weber UM; Peixoto AJ; Weiss SA
    J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
    Kato T; Nagahara A; Kawamura N; Nakata W; Soda T; Matsuzaki K; Hatano K; Kawashima A; Ujike T; Imamura R; Nishimura K; Takada S; Tsujihata M; Yamaguchi S; Takao T; Nakai Y; Nakayama M; Nonomura N; Uemura M
    Anticancer Res; 2021 Nov; 41(11):5811-5816. PubMed ID: 34732455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
    Thibault C; Vano Y; Soulat G; Mirabel M
    Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
    [No Abstract]   [Full Text] [Related]  

  • 56. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient?
    Özyurt E; Özçelik S; Sürmeli H; Çelik M; Ayhan M; Özçelik M
    J Oncol Pharm Pract; 2022 Mar; 28(2):462-465. PubMed ID: 34558355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pituitary adenoma apoplexy with initial presentation mimicking bacterial meningoencephalitis: a case report.
    Huang WY; Chien YY; Wu CL; Weng WC; Peng TI; Chen HC
    Am J Emerg Med; 2009 May; 27(4):517.e1-4. PubMed ID: 19555639
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
    Yekedüz E; Ertürk İ; Tural D; Karadurmuş N; Karakaya S; Hızal M; Arıkan R; Arslan Ç; Taban H; Küçükarda A; Öztaş NŞ; Sever ÖN; Uçar G; Can O; Şendur MA; Demirci U; Kılıçkap S; Çiçin İ; Öksüzoğlu B; Özgüroğlu M; Ürün Y
    Future Oncol; 2021 Dec; 17(35):4861-4869. PubMed ID: 34726480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.